The Life Sciences Intellectual Property/Patent team advised Aktis Oncology, Inc. (“Aktis”) on intellectual-property-related matters related to its upsized initial public offering of 17,650,000 shares of its common stock, at an initial public offering price of $18.00 per share. In addition, the underwriters exercised in full their option to purchase an additional 2,647,500 shares of Aktis’ common stock, at the initial public offering price of $18.00 per share. The sale of the 2,647,500 additional shares is expected to close on January 14, 2026, subject to satisfaction of customary closing conditions. The aggregate gross proceeds from the initial public offering, including the full exercise of the underwriters’ option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $365.4 million. All of the shares of common stock were offered by Aktis. Aktis’ common stock began trading on the Nasdaq Global Select Market on January 9, 2026 under the ticker symbol “AKTS.”
Aktis is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. Aktis’s most advanced pipeline program targets Nectin-4, a miniprotein radioconjugate with multi-indication potential across multiple tumor types. Founded and incubated by MPM BioImpact, Aktis has developed its proprietary miniprotein radioconjugate platform to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors. Designed to maximize tumor killing through high penetration followed by internalization and retention in cancer cells, Aktis’s miniprotein radioconjugates are designed to quickly clear from normal organs and tissues, thereby maximizing anticancer activity while minimizing side effects of treatment. The Aktis platform is isotope-agnostic and further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes.
The Goodwin team was led by Michael Shuster, Maria C. Smith, Kuwabo Mubyana, Christopher Bodle, Catherine Amaya, Chris McKenna, Vicki Vann, Danielle Moten, Tavid Bingham, Svetlana Klein, and Jerri Williams.
For more information on the deal, please read the press release.